Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol

J Diabetes. 2014 Jul;6(4):378-80. doi: 10.1111/1753-0407.12116. Epub 2014 Feb 25.
No abstract available

Keywords: 1,5-anhydroglucitol; GlycoMark®; canagliflozin; sodium-glucose cotransporter 2 inhibitor.

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / analysis
  • Canagliflozin
  • Deoxyglucose / blood*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Double-Blind Method
  • Follow-Up Studies
  • Glucosides / therapeutic use*
  • Glycated Hemoglobin / analysis
  • Humans
  • Prognosis
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Thiophenes / therapeutic use*

Substances

  • Blood Glucose
  • Glucosides
  • Glycated Hemoglobin A
  • Sodium-Glucose Transporter 2 Inhibitors
  • Thiophenes
  • Canagliflozin
  • 1,5-anhydroglucitol
  • Deoxyglucose